EPISODE · Nov 7, 2025 · 22 MIN
Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation
from WTR Small-Cap Spotlight · host Water Tower Research
Send us Fan MailIn this episode of WTR Small-Cap Spotlight, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon to discuss the company’s mission to transform care for addiction and mental health disorders.Tennyson shares Solvonis’ journey from inception to its Phase 3 lead program for alcohol use disorder (AUD), which achieved 86% patient sobriety in prior Phase 2 trials, and details how the company’s **dual R&D strategy—repurposing existing molecules and discovering new small molecules—**has allowed it to progress with exceptional capital efficiency. The discussion also covers the SVN-001 and SVN-002 programs, commercialization strategy, and Solvonis’ strong financial position and runway through 2027 as it works toward redefining treatment for one of the world’s most pervasive unmet medical needs.
What this episode covers
Send us Fan Mail In this episode of WTR Small-Cap Spotlight, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon to discuss the company’s mission to transform care for addiction and mental health disorders. Tennyson shares Solvonis’ journey from inception to its Phase 3 lead program for alcohol use disorder (AUD), which achieved 86% patient sobriety in pri...
NOW PLAYING
Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation
No transcript for this episode yet
Similar Episodes
Jun 12, 2025 ·30m
Apr 22, 2025 ·32m
Apr 17, 2025 ·16m
Feb 27, 2025 ·0m
Dec 16, 2024 ·39m